Listenly

What is the Viagra pivot case and what does it teach about drug discovery flexibility?

Answered at 10:48 in Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast

— questions searchable right now

What is the Viagra pivot case and what does it teach about drug discovery flexibility?

Viagra was initially designed for heart treatment more than 20 years ago, but during trials it showed different indications that led to a different marketplace and different aspect of human health. This demonstrates the importance of maintaining collaborative supplier relationships and curiosity rather than rigid agreements, so companies can uncover unexpected pivots and create an innovative culture.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Viagra was initially designed for heart treatment more than 20 years ago, but during trials it showed different indications that led to a different marketplace and different aspect of human health.

Dave Stowe, Founder and Managing Partner at Adventus · Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast · answer at 10:48

Key takeaways

  • Viagra was initially designed for heart treatment more than 20 years ago, but during trials it showed different indications that led to a different marketplace and different aspect of human health.

Quote to remember

“Somehow you've got to build those relationships. And I feel like when I've seen bad situations happen is people in the pharma space and the finance procurement do not extend it. They say, well, they should come and find me. And I'd say, no, it's the other way around. We need to go to them.”

— Dave Stowe

The full answer · about 1 min

Viagra was initially designed for heart treatment more than 20 years ago, but during trials it showed different indications that led to a different marketplace and different aspect of human health. This demonstrates the importance of maintaining collaborative supplier relationships and curiosity rather than rigid agreements, so companies can uncover unexpected pivots and create an innovative culture.

Key facts

  • Three main phases of clinical trials: Phase One, Two, and Three
  • Biotech spending scale progression: $20 million to $40 million to $80 million to $100 million to $200 million annually in drug development
  • Viagra development timeline: designed for heart treatment over 20 years ago before pivoting to different therapeutic use
  • Preclinical stage triggers: investigational new drug (IND) setup marks transition requiring more investor money and structured relationships
  • Patent protection: limited time period for pharmaceutical companies to recoup investments before drugs lose patent exclusivity and become subject to generic competition

People, companies and topics mentioned

AdventusContract Research Organizations (CROs)PwCOliver WymanHorizon TherapeuticsPurdue PharmaFDAInvestigational New Drug (IND)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00